靜脈免疫球蛋白市場規模、佔有率和成長分析（按產品、分銷管道、應用和地區）- 2025-2032 年產業預測

靜脈免疫球蛋白市場規模在 2023 年價值 129 億美元，預計將從 2024 年的 138.4 億美元成長到 2032 年的 243.2 億美元，預測期內（2025-2032 年）的複合年成長率為 7.3%。

由於幾個關鍵因素，靜脈注射免疫球蛋白 (IVIG) 市場正在經歷強勁成長。突出的因素包括老年人口的不斷成長、免疫不全症盛行率的不斷上升以及 IVIG 治療方案的廣泛接受。此外，患有出血性疾病和慢性脫髓鞘多發性神經炎(CIDP) 的患者數量不斷增加，導致 IVIG 的仿單標示外使用增加。醫療保健領域的大量投資正在進一步推動市場擴張。此外，自體免疫疾病和其他病理狀況的發病率不斷上升也推動了對 IVIG 產品的需求，凸顯了它們在滿足多樣化醫療保健需求方面的重要作用。隨著這些動態的不斷發展，IVIG 市場可能在未來幾年內持續成長。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

靜脈注射免疫球蛋白市場規模（按產品和複合年成長率） (2025-2032)

• 市場概況
• IGG
• IGA
• IGM
• IGE
• IGD

靜脈注射免疫球蛋白市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 專業藥房
• 其他

靜脈注射免疫球蛋白市場規模（依應用分類）及複合年成長率（2025-2032）

• 市場概況
• 免疫不全症
• CIDP
• 低丙種球蛋白血症
• 先天性愛滋病
• 慢性淋巴性白血病
• 重症肌無力
• 多灶性運動神經病變
• 免疫球蛋白
• 川崎病
• 格林-巴利綜合症
• 其他

靜脈注射免疫球蛋白市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司詳細資訊
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• CSL Behring（Australia）
• Grifols, SA（Spain）
• Octapharma AG（Switzerland）
• Kedrion SpA（Italy）
• Bio Products Laboratory Ltd.（United Kingdom）
• Biotest AG（Germany）
• China Biologic Products Holdings, Inc.（China）
• LFB SA（France）
• Shanghai RAAS Blood Products Co., Ltd.（China）
• ADMA Biologics, Inc.（United States）
• Sanquin Blood Supply Foundation（Netherlands）
• Kamada Ltd.（Israel）
• Emergent BioSolutions Inc.（United States）
• Hualan Biological Engineering Inc.（China）
• Green Cross Corporation（South Korea）
• Bharat Serums and Vaccines Limited（India）
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.（China）
• Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.（China）
• Guangdong Shuanglin Bio-Pharmacy Co., Ltd.（China）
• Nanjing Xinbai Pharmaceutical Co., Ltd.（China）

結論和建議

Intravenous Immunoglobulin Market size was valued at USD 12.9 billion in 2023 and is poised to grow from USD 13.84 billion in 2024 to USD 24.32 billion by 2032, growing at a CAGR of 7.3% during the forecast period (2025-2032).

The intravenous immunoglobulin (IVIG) market is witnessing robust growth driven by several pivotal factors. The rising geriatric population, increasing prevalence of immunodeficiency disorders, and broader acceptance of IVIG treatment options are notable contributors. Additionally, the off-label use of IVIG is expanding, spurred by a growing demographic of patients suffering from bleeding disorders and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Significant investments in the healthcare sector further bolster market expansion. The escalating rates of autoimmune diseases and other pathological conditions also amplify the demand for IVIG products, highlighting their essential role in meeting diverse healthcare needs. As these dynamics evolve, the IVIG market is positioned for sustained growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Intravenous Immunoglobulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Intravenous Immunoglobulin Market Segments Analysis

Global Intravenous Immunoglobulin Market is segmented by Product, Distribution Channel, Application and region. Based on Product, the market is segmented into IGG, IGA, IGM, IGE and IGD. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Specialty Pharmacies and Other. Based on Application, the market is segmented into Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal motor neuropathy, ITP, Kawasaki disease, Guillain-Barre syndrome and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Intravenous Immunoglobulin Market

The increasing adoption of intravenous immunoglobulin (IVIG) therapy as the primary treatment option for various rare immunological and neurological disorders, particularly primary immunodeficiency (PI) and related conditions, serves as a key driver for the growth of the intravenous immunoglobulin market. This widespread acknowledgment of IVIG as a first-line therapeutic approach underscores its effectiveness and vital role in the successful management of these diseases. As more healthcare providers and patients recognize the benefits of IVIG, the demand for this therapy continues to rise, further solidifying its importance in treating complex immunological conditions.

Restraints in the Intravenous Immunoglobulin Market

The financial implications associated with the diagnosis and treatment of demyelinating diseases create a substantial obstacle for the intravenous immunoglobulin (IVIG) market. One of the most pressing challenges is the escalating costs associated with IVIG therapy, which significantly hinder market growth. IVIG treatment generally requires administration every three to four weeks, resulting in roughly 12 to 16 treatment sessions per year. Given the average expenditure for IVIG is approximately USD 73.89 per gram, this leads to an estimated total annual cost of around USD 10,000. Such high prices can deter patients from accessing necessary treatments, putting further strain on market expansion.

Market Trends of the Intravenous Immunoglobulin Market

The Intravenous Immunoglobulin (IVIG) market is witnessing dynamic growth fueled by several significant trends transforming its landscape. A notable increase in IVIG utilization for neurological disorders underscores its expanding therapeutic applications beyond conventional uses, reflecting a broader acceptance in clinical settings. Furthermore, the incorporation of personalized medicine approaches into IVIG therapies is reshaping treatment protocols, aligning therapies with specific patient needs for improved outcomes. Additionally, the rise of novel immunomodulatory treatments contributes to this evolving market by introducing innovative therapeutic options, enhancing the treatment landscape, and paving the way for future advancements in patient care and immunoglobulin therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Intravenous Immunoglobulin Market Size by Product & CAGR (2025-2032)

• Market Overview
• IGG
• IGA
• IGM
• IGE
• IGD

Global Intravenous Immunoglobulin Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies
• Other

Global Intravenous Immunoglobulin Market Size by Application & CAGR (2025-2032)

• Market Overview
• Immunodeficiency diseases
• CIDP
• Hypogammaglobulinemia
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal motor neuropathy
• ITP
• Kawasaki disease
• Guillain-Barre syndrome
• Others

Global Intravenous Immunoglobulin Market Size & CAGR (2025-2032)

• North America (Product, Distribution Channel, Application)
  • US
  • Canada
• Europe (Product, Distribution Channel, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Distribution Channel, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Distribution Channel, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Distribution Channel, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings, Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai RAAS Blood Products Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADMA Biologics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanquin Blood Supply Foundation (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kamada Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Engineering Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Serums and Vaccines Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guangdong Shuanglin Bio-Pharmacy Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nanjing Xinbai Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations